| ²é¿´: 148 | »Ø¸´: 2 | |||
| µ±Ç°Ö÷ÌâÒѾ´æµµ¡£ | |||
ashaoÒø³æ (ÖøÃûдÊÖ)
|
[½»Á÷]
ÇóÖú£¬ÎªÊ²Ã´Õâ¾ä»°·ÒëµÃ×ÔÏàì¶Ü°¡£¿
|
||
|
Furthermore, it would be expected that the constraining¡¾ CR1/ CR2 interactions seen in sErbB3¡¿ and ¡¾the unactivated¡¿ EGFR would not be tolerated¡¾ in a receptor such as ErbB2 that does not bind ligand¡¿, since the removal of¡¾ this CR1/ CR2 ¡¿constraint and the activation¡¾ of EGFR, ErbB3, and ErbB4¡¿ appears to be dependent on ligand binding. ·Ò롪¡ª ½øÒ»²½Ëµ£¬¿ÉÒÔÔ¤ÆÚµÄÊÇ£¬Ô¼Êø¡¾ÔÚsErbB3Öмûµ½µÄCR1CR2½»¸Ð¡¿ºÍ¡¾Î´±»¼¤»îµÄ¡¿EGFR¶ÔÓÚ¡¾Ã»ÓÐÅäÌå¼üºÏµÄErbB2ÊÜÌå¡¿²»ÄܽÓÊÜ£»ÒòΪȥ³ýÕâÖÖ¡¾CR1/CR2µÄ¡¿Ô¼ÊøºÍ¡¾¼¤»î¡¿£Å£Ç£Æ£ÒµÈÐèÒªÒÀ¿¿ÅäÌå¼üºÏ¡£ £½£½£½£½£½£½£½£½£½£½£½£½£½£½Ò²¾ÍÊÇ˵£½£½£½£½£½£½£½£½£½£½£½ Èç¹ûûÓÐÅäÌ壬ÄÇô²»ÄÜÈÝÈÌ£¨Ô¼Êø+²»¼¤»î£©£» ÕâÊÇÒòΪ£¬²»£¨Ô¼Êø+²»¼¤»î£©ÐèÒªÒÀ¿¿ÅäÌå¡£ Õâ²»ÊÇ×ÔÏàì¶Üô£¿ |
» ²ÂÄãϲ»¶
0856²ÄÁÏ»¯¹¤µ÷¼Á ×Ü·Ö330
ÒѾÓÐ13È˻ظ´
330·ÖÇóµ÷¼Á
ÒѾÓÐ5È˻ظ´
291Çóµ÷¼Á
ÒѾÓÐ3È˻ظ´
086000ÉúÎïÓëÒ½Ò©µ÷¼Á
ÒѾÓÐ8È˻ظ´
352·Ö-085602-Ò»Ö¾Ô¸985
ÒѾÓÐ3È˻ظ´
291Çóµ÷¼Á
ÒѾÓÐ4È˻ظ´
309Çóµ÷¼Á
ÒѾÓÐ4È˻ظ´
0856Çóµ÷¼Á
ÒѾÓÐ13È˻ظ´
0703»¯Ñ§
ÒѾÓÐ11È˻ظ´
329Çóµ÷¼Á
ÒѾÓÐ7È˻ظ´
ashao
Òø³æ (ÖøÃûдÊÖ)
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ½ð±Ò: 3269.8
- É¢½ð: 265
- ºì»¨: 4
- Ìû×Ó: 2194
- ÔÚÏß: 193Сʱ
- ³æºÅ: 230992
- ×¢²á: 2006-03-26
- ÐÔ±ð: GG
- רҵ: Ó¦Óø߷Ö×Ó»¯Ñ§ÓëÎïÀí
2Â¥2008-04-22 21:53:56
ashao
Òø³æ (ÖøÃûдÊÖ)
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ½ð±Ò: 3269.8
- É¢½ð: 265
- ºì»¨: 4
- Ìû×Ó: 2194
- ÔÚÏß: 193Сʱ
- ³æºÅ: 230992
- ×¢²á: 2006-03-26
- ÐÔ±ð: GG
- רҵ: Ó¦Óø߷Ö×Ó»¯Ñ§ÓëÎïÀí
3Â¥2008-04-24 08:17:34














»Ø¸´´ËÂ¥